Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals statistics

91 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: Sep 5, 2024
Fundamentals through: Jun 30, 2026
Share price as of: Nov 6, 2026

Valuation ratiosIndustry

Market Cap: $257.18M; –
Enterprise Value: $83.17M; –
PE Ratio: 11.09; –
PS Ratio: 4.00; –
PB Ratio: 1.36; –
P/TBV Ratio: 1.36; –
P/FCF Ratio: 21.71; –
P/OCF Ratio: 19.93; –

Enterprise valuationIndustry

EV / Sales: 1.29; –
EV / EBITDA: 2.98; –
EV / EBIT: 2.98; –
EV / FCF: 7.02; –

Share statisticsIndustry

Shares Outstanding: 50M; –
Shares Change (YoY): 0.73%; –
Float: 50M; –
Shares Held by Insiders: 0.00%; –

Short sellingIndustry

Short Interest: 15,683; –
Short Interest Change: 30.1%; –
Days to Cover: 2.87; –

Stock price statisticsIndustry

52-Week High: $8.92; –
52-Week Low: $4.81; –
20-Day Moving Average: $5.12; –
50-Day Moving Average: $5.59; –
200-Day Moving Average: $6.71; –
Average True Range (14): $0.28; –
Price Change (1 Week): 0.59%; –
Price Change (1 Month): -8.93%; –
Price Change (3 Months): -24.3%; –
Price Change (6 Months): -25.2%; –
Price Change (YTD): -39.9%; –
Price Change (1 Year): -28.9%; –
Price Change (3 Years): -48.5%; –
Price Change (5 Years): -80.6%; –
Price Change (10 Years): -14.3%; –
Average Volume (10 Days): 4,550; –
Average Volume (20 Days): 5,530; –
Average Volume (90 Days): 10,989; –
Relative Volume: 0.39; –
Relative Strength Index (14): 44.0; –
Volatility (1 Year): 48.9%; –
Beta (5 Years): 0.81; –

MarginsIndustry

Gross Margin: 82.9%; –
Operating Margin: 43.4%; –
Pretax Margin: 50.9%; –
Profit Margin: 36.0%; –
EBITDA Margin: 43.4%; –
FCF Margin: 18.4%; –

Returns on capitalIndustry

Return on Equity (ROE): 13.4%; –
Return on Assets (ROA): 12.2%; –
Return on Invested Capital (ROIC): 153.2%; –
Return on Capital Employed (ROCE): 14.6%; –

Financial positionIndustry

Current Ratio: 14.72; –
Quick Ratio: 14.24; –

GrowthIndustry

Revenue Growth (YoY): 5.23%; –
Net Income Growth (YoY): 0.24%; –
EPS Growth (YoY): 0.00%; –
FCF Growth (YoY): -56.3%; –

EfficiencyIndustry

Asset Turnover: 0.34; –
Inventory Turnover: 2.09; –
Revenue Per Employee: $1.29M; –
Profits Per Employee: $463.56K; –
Employee Count: 50; –
WACC: 8.89%; –

Income statement (TTM)Industry

Revenue: $64.32M; –
Gross Profit: $53.34M; –
Operating Income: $27.92M; –
Pretax Income: $32.72M; –
Net Income: $23.18M; –
EBITDA: $27.92M; –
EPS (Diluted): $0.46; –

Balance sheetIndustry

Cash & Short-Term Investments: $174.01M; –
Net Cash (Debt): $174.01M; –
Net Cash Per Share: $3.45; –
Equity (Book Value): $188.62M; –
Book Value Per Share: $3.74; –
Tangible Book Value: $188.49M; –
Working Capital: $183.18M; –

Cash flow (TTM)Industry

Operating Cash Flow: $12.91M; –
Capital Expenditures: -$1.06M; –
Free Cash Flow: $11.85M; –
FCF Per Share: $0.23; –

Dividends and yieldsIndustry

Earnings Yield: 9.01%; –
FCF Yield: 4.61%; –
Payout Ratio: 7.20%; –
FCF Payout Ratio: 14.1%; –

Taxes and interestIndustry

Income Tax: $9.54M; –
Effective Tax Rate: 29.2%; –

Scores and fair valueIndustry

Graham Number: $6.22; –
Graham Upside: 22.0%; –
Altman Z-Score: 12.36; –
Piotroski F-Score: 6; –

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

Period	CLVLF	S&P 500	Difference	CLVLF per year	S&P 500 per year
1 month	-14.3%	+0.6%	−14.9 pts
3 months	-17.2%	+3.4%	−20.6 pts
Year to date	-34.4%	+13.3%	−47.7 pts
1 year	-32.0%	+16.6%	−48.6 pts
3 years	-51.2%	+86.4%	−137.6 pts	-21.3%	+23.1%
5 years	-83.1%	+81.9%	−164.9 pts	-29.9%	+12.7%
10 years	-2.9%	+318.9%	−321.8 pts	-0.3%	+15.4%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 15, 2026.

2M CLVLF shares were sold short on Oct 15, 2026, up 0.1% from the previous report. At recent volumes it would take 1000.0 days to buy them back.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 15, 2026	2,356,283	+0.1%	427	1000.0
Sep 30, 2026	2,354,775	+0.3%	165	1000.0
Sep 15, 2026	2,348,191	+0.3%	105	1000.0
Aug 31, 2026	2,341,889	-2.4%	368	1000.0
Aug 14, 2026	2,398,653	-0.4%	12,282	195.3
Jul 31, 2026	2,408,210	-0.7%	22	1000.0
Jul 15, 2026	2,425,193	-0.5%	0	1000.0
Jun 30, 2026	2,437,367	+2.5%	2	1000.0
Jun 15, 2026	2,376,828	+2.2%	273	1000.0
May 29, 2026	2,326,462	+1.9%	672	1000.0
May 15, 2026	2,284,026	+3.3%	933	1000.0
Apr 30, 2026	2,210,419	+15.6%	51	1000.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLVLF.

Compare: CLVLF vs VRDN · CLVLF vs BFRI · CLVLF vs PLX · CLVLF vs FBIO · CLVLF vs ETON

Revenue growth5.2% · median 17.8%

Gross margin82.9% · median 69.2%

Operating margin43.4% · median -14.2%

Net margin36.0% · median 23.5%

Company	Revenue	Growth
ETON	$141.06M	+100.6%
PLX	$80.62M	+30.1%
FBIO	$68.47M	+15.5%
CLVLF	$64.32M	+5.2%
BFRI	$46.18M	+17.8%
VRDN	$26.31M	-62.8%

Company

Exchange: OTC
Industry: American Depositary Receipts
Fiscal year ends: June 30
Employees: 50
SEC CIK: 1290877

Advertisement
300 × 250

See a number that looks wrong?